 |
Notes to Consolidated Financial Statements
|
|
Other intangible assets at September 30 consisted of:
| |
2005 |
2004 |
|
| |
Gross
Carrying
Amount |
|
Accumulated
Amortization |
|
Gross
Carrying
Amount |
|
Accumulated
Amortization |
|
|
| Amortized intangible |
|
|
|
|
|
|
|
|
|
|
|
|
| assets |
|
|
|
|
|
|
|
|
|
|
|
|
| Core and developed |
|
|
|
|
|
|
|
|
|
|
|
|
| technology |
$ |
274,615 |
|
$ |
109,234 |
|
$ |
297,342 |
|
$ |
108,801 |
|
| Patents, trademarks, |
|
|
|
|
|
|
|
|
|
|
|
|
| and other |
|
338,391 |
|
|
246,060 |
|
|
311,682 |
|
|
229,047 |
|
|
| |
$ |
613,006 |
|
$ |
355,294 |
|
$ |
609,024 |
|
$ |
337,848 |
|
|
| Unamortized |
|
|
|
|
|
|
|
|
|
|
|
|
| intangible assets |
|
|
|
|
|
|
|
|
|
|
|
|
| Trademarks |
$ |
9,227 |
|
|
|
|
$ |
10,831 |
|
|
|
|
|
Intangible amortization expense was $33,405, $31,467 and $31,413 in 2005, 2004 and 2003, respectively. The estimated aggregate amortization expense for the fiscal years ending September 30, 2006 to 2010 are as follows: 2006–$32,600; 2007–$32,600; 2008–$31,500; 2009–$29,000; 2010–$27,700.
During 2003, the Company decided to discontinue the development of certain products and product applications associated with the BD IMAGN instrument platform in the Biosciences segment. As a result, the Company recorded an impairment loss of $26,717 in Cost of products sold. This loss included the write down of $25,230 of core and developed technology, $960 of indefinite-lived trademarks and $527 of licenses.
|
